The Ottawa Hospital’s Biotherapeutics Manufacturing Centre is proud to play a role in a wide range of research projects, some of which are profiled below.

Medicine’s future: living drugs

Nov 28, 2021 - The Ottawa Hospital’s Biotherapeutics Manufacturing Centre harnessing the life-saving power of biological therapies


COVID-19 booster shot study recruits Ottawa-area volunteers

Sep 29, 2021 - Ottawa-area adults who are fully vaccinated with a COVID-19 mRNA vaccine are invited to participate in a clinical trial of a locally developed COVID-19 vaccine candidate, as a third dose or late booster vaccine. To be eligible, participants must have received their second mRNA vaccine dose at least four months ago, must be between the ages of 18 and 54, and must be in good health.


$2.4 M grant to help researchers develop gene and cell therapies for a leading cause of blindness

Sep 15, 2021 - A team led by Dr. Catherine Tsilfidis has received $2.4 M from the Ontario Research Fund to develop treatments for retinal diseases, a leading cause of blindness.


Biomanufacturing partnership boosts Canada’s life-saving treatment and vaccine capacity

Sep 13, 2021 - As Canada seeks to rebuild its biomanufacturing sector and support made-in-Canada solutions to global health challenges, The Ottawa Hospital, the University of Alberta and BioCanRx have collaborated to create Canada’s first full-service, end-to-end biomanufacturing solution for academic and industrial clients.


Biotherapeutics: the future of medicine

Nov 28, 2021 - World-class biotherapeutics facility at The Ottawa Hospital uses cells, genes and viruses to create unique life-saving treatments


Experts on call: Stem cells, gene therapy and biotherapeutics

Apr 22, 2021 - Could biotherapeutics be the key to the next wave of medical breakthroughs? Join this lively discussion to learn how researchers at The Ottawa Hospital are using biological materials like cells, genes and viruses to heal the body and fight disease.


Grateful COVID-19 patient gives back by participating in research

Apr 13, 2021 - Sharon Charlebois doesn’t remember much about the 25 days she spent at The Ottawa Hospital fighting a severe case of COVID-19 in January 2021. Now that she’s recovering at home with her husband, some memories come back to her in flashes.


The rise of point-of-care cell manufacturing

Mar 12, 2021 - Decentralized approach represents a paradigm shift in the way Canada studies, commercializes and delivers stem cell treatments for serious diseases


Ottawa-area residents invited to participate in COVID-19 vaccine trial

Mar 9, 2021 - Healthy adults are invited to participate in a clinical trial at The Ottawa Hospital to test a COVID-19 vaccine candidate developed by VBI Vaccines Inc., a biotechnology company with Ottawa-based research and development facilities.


Cancer team awarded $5M for cell-based immunotherapy research

Mar 3, 2021 - Researchers at The Ottawa Hospital and the University of Ottawa are partnering with colleagues across the country to expand Canada’s capacity to develop new cell-based immunotherapies for cancer with a $5.2 million grant from the Canada Foundation for Innovation.


The Ottawa Hospital manufactures COVID-19 vaccines for clinical trials

Feb 25, 2021 - The Ottawa Hospital’s Biotherapeutics Manufacturing Centre (BMC) is manufacturing three COVID-19 vaccines for human clinical trials, filling a critical gap in Canada’s vaccine manufacturing capacity.


One small step for blood cancer patients, one giant step for Canadian cancer patients of all stripes

Feb 25, 2021 - The Canadian-Led Immunotherapies in Cancer (CLIC) research program is building Canada’s capacity for innovation in CAR-T therapy, with support from BioCanRx, The Ottawa Hospital, BC Cancer and the Ontario Institute for Cancer Research


Experimental stem cell therapy a potential weapon against COVID-19

Jun 25, 2020 - Drs. Duncan Stewart, Shane English, Dean Fergusson and colleagues have launched a clinical trial to test MSCs in people with severe COVID-19.


Vaccines and viral immunotherapies: unique Canadian program provides training to manufacture biotherapeutics

Nov 21, 2020 - As COVID-19 highlights the urgent need to increase vaccine manufacturing around the world, a unique training program is bolstering Canada’s capacity to manufacture vaccines, as well as viral immunotherapies for cancer and other emerging biotherapeutics.


$1M grant to support manufacturing of COVID-19 treatments and vaccines at The Ottawa Hospital and uOttawa

Nov 6, 2020 - Researchers from The Ottawa Hospital and the University of Ottawa have been awarded $1,050,000 from the Canada Foundation for Innovation to support facilities for manufacturing innovative treatments and vaccines for COVID-19.


Gene therapy for deadly newborn lung disease shows promise in mice

Oct 26, 2020 - One in a million babies are born with Surfactant Protein B deficiency, a genetic disorder in the lungs that will kill them before their first birthday. The only cure is a lung transplant.


The Ottawa Hospital and uOttawa launch new cancer immunotherapy research projects with funding from BioCanRx

Sep 22, 2020 - BioCanRx, Canada’s Immunotherapy Network, today announced funding of $10M for 14 cancer immunotherapy research projects and eight core and biomanufacturing facilities across the country. Researchers at The Ottawa Hospital (TOH) and the University of Ottawa (uOttawa) are playing a key role in the following seven projects:


Harnessing cancer-fighting viruses to develop a COVID-19 vaccine

Jun 25, 2020 - Drs. Carolina Ilkow, John Bell and colleagues are harnessing their expertise in making oncolytic (cancer-fighting) viruses to develop a vaccine against COVID-19, in partnership with scientists and clinicians in Canada and around the world.


COVID-19 research on cell therapy, drug screening and marginalized populations funded through Ontario’s Rapid Research Fund

May 21, 2020 - Researchers from The Ottawa Hospital, affiliated with the University of Ottawa, have been awarded almost $2 million from Ontario’s COVID-19 Rapid Research Fund for three research projects that could help in the fight against the virus. These three projects were among the first 15 proposals to receive funding from the Ontario COVID-19 Rapid Research Fund.


Cancer-killing viruses provide inspiration for COVID-19 vaccine

Apr 28, 2020 - While physical distancing has slowed the spread of COVID-19, the vast majority of people around the world remain susceptible to the virus. That’s why most experts believe we won’t be able to fully find a new normal until a vaccine is developed. At The Ottawa Hospital and the University of Ottawa, Dr. Carolina Ilkow and Dr. John Bell are harnessing their pioneering research on cancer-fighting viruses to create a vaccine for COVID-19, in partnership with colleagues across the country and around the world.


Harnessing stem cells and regenerative medicine to fight COVID-19

Apr 23, 2020 - Researchers from The Ottawa Hospital and the University of Ottawa have been awarded $490,000 from the Stem Cell Network for two research projects that could help in the fight against COVID-19. These peer-reviewed grants are part of an overall investment by the Stem Cell Network of $675,000 in COVID-19 research across Canada.


Researchers join the fight against COVID-19

Apr 2, 2020 - As hospitals and communities band together to fight COVID-19, researchers at The Ottawa Hospital are harnessing their unique expertise and resources to help.


The promise of CAR-T therapy for cancer: meta-analysis shows the big picture

Aug 14, 2019 - CAR-T therapy, which uses a patient’s own genetically modified immune cells, is one of the most exciting advances in cancer treatment. To get a big picture view of the field, Drs. Manoj Lalu and Dean Fergusson led a team that analyzed data from nearly 1,000 patients who participated in 60 different CAR-T trials.


Patients and clinical trial experts key to upcoming made-in-Canada CAR-T clinical trial

Mar 1, 2019 - Researchers at The Ottawa Hospital and the University of Ottawa are known around the world for their expertise in designing and leading clinical trials, and they're now applying this knowledge to create a made-in-Canada approach for CAR-T cell clinical trials. CAR-T therapy uses a patient's own genetically engineered immune cells to attack their cancer.


Experimental stem cell therapy tested for rare lung disease

Apr 30, 2018 - A Canadian-led research team has launched a clinical trial of an experimental stem cell therapy for pulmonary arterial hypertension. This rare and deadly disease occurs when the arteries that supply blood to the lungs become so damaged that blood can’t flow properly to take up oxygen. It can strike anyone at any age, and typically affects women often in their prime. In some cases, pulmonary hypertension is caused by a defective gene, but in most cases the cause is unknown.